MYC and colorectal carcinoma: Moreover, ARI was the only treatment able to counteract the propensity of IFN-α and azacitidine to slightly increase the expression of c-Myc, a pivotal epigenetic-regulated transcription factor whose expression is directly correlated with the metastatic phenotype of CRC cells [35] (Figure 2E).